CA0079755017 - Common Stock
AETERNA ZENTARIS INC
NASDAQ:AEZS (4/24/2024, 7:00:00 PM)
1.97
0 (0%)
Æterna Zentaris, Inc. is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. The company is headquartered in Summerville, New Brunswick and currently employs 21 full-time employees. The firm is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The firm's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The firm is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.
AETERNA ZENTARIS INC
315 Sigma Drive
Summerville NEW BRUNSWICK 29486
P: 18439003223
CEO: Paulini Klaus
Employees: 21
Website: https://www.zentaris.com/
AEZS stock results show that AEterna Zentaris missed analyst estimates for earnings per share the fourth quarter of 2023.
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected...
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value...
Here you can normally see the latest stock twits on AEZS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: